It was observed that 10% of urine culture isolates of enterococci tested for antimicrobial susceptibility failed to grow on commercially prepared MuellerHinton agar with low levels of thymidine and thymine. All strains could utilize exogenous thymidine and thymine and required only low levels (0.4-,ug disk) to support growth. All thymidine-thymine-requiring strains were resistant to trimethoprim-sulfamethoxazole.
It was observed that 10% of urine culture isolates of enterococci tested for antimicrobial susceptibility failed to grow on commercially prepared MuellerHinton agar with low levels of thymidine and thymine. All strains could utilize exogenous thymidine and thymine and required only low levels (0.4-,ug disk) to support growth. All thymidine-thymine-requiring strains were resistant to trimethoprim-sulfamethoxazole.
Trimethoprim-sulfamethoxazole (TMP-SMZ) is an effective antimicrobial combination which acts by sequential blockade in the metabolic pathways for synthesis of folates (8). Organisms which can use exogenous end products of the folate pathway will be resistant to TMP-SMZ when such end products are present (11) . Therefore, in vitro susceptibility testing of TMP-SMZ is dependent upon utilization of a medium free of such exogenous metabolites since they will allow bypass of the blockade in a noncompetitive manner. Strains lacking thymidylate synthetase require folates (usually thymidine or thymine) and may not grow on media low in folate pathway end products. Clinical isolates of such strains are usually reported to the physician without antimicrobial susceptibility determinations, and the patient is at risk of being treated with an ineffective drug.
In 1972, Barker and co-workers (2) reported the isolation of six strains of Enterobacteriaceae, including two Proteus mirabilis and four Escherichia coli strains which were resistant to TMP-SMZ due to a requirement for exogenous thymidine. Five of the six isolates were from patients treated with TMP-SMZ. Subsequently, there have been a number of reports of clinical isolates resistant to TMP-SMZ due to a requirement for either exogenous thymidine or thymine. In 1973, Lacey and Lewis (12) reported the isolation of a thymidine-requiring Staphylococcus aureus from the sputum of a fibrocystic child previously treated with TMP-SMZ. Also in 1973, Okubadejo and Maskell (16) reported the isolation of three strains of thymine-requiring P. mirabilis from the urine of three patients on long-term TMP-SMZ therapy. In 1974, Tapsall et al. (18) reported the isolation of six strains of thymine-dependent E. coli from the urine of six patients receiving TMP-SMZ therapy. Also in 1974, Tanner Quantitative urine cultures were done by means of the calibrated loop method (0.001 ml) on both Trypticase soy agar (BBL Microbiology Systems) with 5% sheep blood and MacConkey agar. Organisms from cultures with growth of a predominant species at 10,000 colony-forming units per ml or greater were identified and tested for antibiotic susceptibility by the disk diffusion method set forth by the National Committee for clinical Laboratory Standards (15) . Enterococci which failed to grow, or to grow adequately, for susceptibility testing on MHII, or MHII with 5% sheep blood (MHBII), were retested on MHA, or MHA with 5% sheep blood (MHAB), from another manufacturer (Scott Laboratories, Inc., Fiskeville, R.I.) with an apparently more variable thymidine content. Except for TMP-SMZ, results of susceptibility testing of enterococci on the media from the two manufacturers were quite similar.
To determine whether the lack of growth on MHII and MHBII was due to inhibition of growth or lack of adequate nutrients, we ascertained the abilities of a "staphylococcus streak" (S. aureus ATCC 25923), thymidine and thymine disks (0.4 ytg/disk) ( We also found six clinical isolates of organisms other than enterococci which were unable to grow adequately for susceptibility testing on MHII or MHBII. They included two strains of P. aeruginosa, three strains of E. coli, and one strain of P. mirabilis. These strains were screened to determine whether they required higher levels of thymidine or thymine for growth than that supplied by MHII agar. The strains of P. aeruginosa and E. coli did not grow adjacent to the staphylococcus streak on MHH or around thymine or thymidine disks with concentrations up to 100 ug, suggesting a need for nutrients other than, or in addition to, thymine or thymidine and other supplements provided by the staphylococcus streak (e.g., nicotinamide adenine dinucleotide and vitamin B6). The strain of P. mirabilis, similar to the thy-enterococci reported here, grew on MHII agar with the addition of a 0.4-,Ig disk of either thymine or thymidine.
The eight thy-enterococci were isolated from six patients ( Table 1) . Charts of five of the patients were available for review. Two patients had been receiving TMP-SMZ therapy for a short period (1 week and 5 weeks) before isolation of the thy-organisms. Two patients were on long-term TMP-SMZ treatment for recurrent urinary tract infections. The fifth patient had no recorded history of treatment with TMP-SMZ and was reported to be allergic to sulfonamides.
DISCUSSION
The laboratory had been alerted to the possibility of the failure of enterococci to grow on MHII and MHBII by the chance selection of the thy-quality control strain. We were, however, surprised at the incidence of thy-enterococci (10.0% of urine culture enterococcus isolates tested for antibiotic susceptibility if multiple thy-isolates from the same patient are eliminated). Because of the high rate of thy-strains, we repeated the study over an additional 1-month period (1 to 31 March 1980) to verify our original observation and found the rate quite similar, but with several differences that should be noted. During March, 12 of 82 enterococci tested for susceptibility were found to be thy-. However, 6 of the 12 thy-strains were repeat isolates detected throughout the month in the urine of one patient. Nine of the twelve strains were urine isolates, one was from dialysis fluid, one was from a wound exudate, and one was from a decubitus ulcer. Eliminating multiple thy-strains from the same patient, the adjusted rate for March was 9.1% (7/77) from all body sites as compared with an adjusted rate of 6.4% (6/94) for December. Eight of the March isolates were identified as S. faecalis subsp. liquefaciens, and four were identified as S. faecalis subsp. faecalis (five S. faecalis subsp. liquefaciens strains were isolated from one patient throughout the month).
Andrew (1) reported that laboratory-induced thy-mutants of S. faecalis required low levels of thymine (2 jig/ml). Maskell et al.(14) reported that the four thy-clinical isolates of S. faecalis studied grew around low-content (2 ,ug) thymine disks on Iso-Sensitest agar. Our observation of growth around a 0.4-,ug thymidine or thymine disk on MHII and that 0.63 ,ug of thymidine or thymine per ml supported growth of all strains in MH broth suggests that the thyf strains reported here also required only low levels of thymidine or thymine. Maskell et al. (14) reported that only one thystrain (an E. coli) was isolated from a patient after a short course of TMP-SMZ therapy before July 1975, but after that date thy-strains from patients on short-course therapy with TMP-SMZ were seen with increasing frequency. In this study, all but one of the patients (4 of 5) whose records were available for evaluation were receiving TMP-SMZ treatment before the isolation of the thy-S. faecalis strains. Two 
